NMD is a process that removes erroneously spliced mRNAs with truncated ORFs that could give rise to gain-of-function or dominant-negative protein products (Dreyfuss et al, 2002; Lewis et al, 2003; Sterne-Weiler et al, 2013; Maslon et al, 2014; Floor & Doudna, 2016; Aviner et al, 2017), and splicing alterations associated with cancer-specific splicing factor mutations have been shown to be substrates of NMD (Yip et al, 2017; Rahman et al, 2020). Here, SLU7 is linked to cancer.